10 December 2016

DnB Healthcare Prize 2016

Press release: Oncoinvent selected to present as a finalist in DnB Healthcare Prize 2016 competition.


For the second year in a row, the DNB Healthcare Prize will be presented on the 15th of December during the the 7th annual DnB Healthcare Conference. The competition is for companies in an early growth phase.

The winner of the completion will be awarded NOK 1 million.

The companies selected for the DNB Healthcare Prize 2016 final competition include:

  1. SpinChip Diagnostics AS
  2. Vectron Biosolutions AS
  3. Otivio AS
  4. Prediktor Medical AS
  5. EpiGuard AS
  6. Oncoinvent AS

Anders Månsson

Chief Executive Officer


Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.